Wuxi Bio (02269) expects a year-on-year increase of about 56% in profits attributable to equity shareholders of the company in the first half of the year.

WUXI BIO (02269) announced that the group expects to achieve a revenue growth of approximately 16% year-on-year in the first half of 2025; gross profit margin is expected to increase by about 3.6% year-on-year; profit and profit attributable to equity shareholders of the company are expected to increase by approximately 54% and 56% respectively compared to the same period last year; and after adjusting for share-based compensation expenses, foreign exchange gains and losses, and equity investment gains and losses, the company's adjusted net profit under non-International Financial Reporting Standards is expected to increase by approximately 11%. The announcement stated that the expected performance growth is mainly attributed to the following factors: the successful execution of the "Follow and Win Molecule" strategy, as well as the leading technology platform, industrys best project delivery time, and excellent track record of project execution driving revenue growth for the group; based on rapidly developing technology platforms such as ADCs (antibody-drug conjugates) and bispecific antibodies, the group has expanded its service offerings to the biopharmaceutical industry including research discovery, pre-IND development, clinical and commercial production; revenue growth generated by multiple advanced technologies of the group's research services; utilization of existing and new production capabilities, including ramping up production capacity at the European manufacturing base; cost savings and efficiency improvements achieved by the group through the WUXI BIO Lean Operations Management System (WBS) and digital solutions; and investment gains obtained by the company through investment and incubation portfolios.